Compare TWIN & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TWIN | PBYI |
|---|---|---|
| Founded | 1918 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 224.5M | 263.4M |
| IPO Year | N/A | N/A |
| Metric | TWIN | PBYI |
|---|---|---|
| Price | $15.79 | $5.62 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $12.00 | $7.00 |
| AVG Volume (30 Days) | 30.0K | ★ 531.2K |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | ★ 1.03% | N/A |
| EPS Growth | N/A | ★ 59.87 |
| EPS | 0.02 | ★ 0.74 |
| Revenue | ★ $347,837,000.00 | $211,995,000.00 |
| Revenue This Year | $10.79 | N/A |
| Revenue Next Year | $8.43 | N/A |
| P/E Ratio | $841.48 | ★ $7.16 |
| Revenue Growth | ★ 14.24 | N/A |
| 52 Week Low | $6.16 | $2.58 |
| 52 Week High | $17.08 | $6.12 |
| Indicator | TWIN | PBYI |
|---|---|---|
| Relative Strength Index (RSI) | 56.99 | 62.87 |
| Support Level | $15.44 | $4.84 |
| Resistance Level | $16.27 | $5.11 |
| Average True Range (ATR) | 0.61 | 0.20 |
| MACD | 0.05 | 0.07 |
| Stochastic Oscillator | 85.85 | 97.08 |
Twin Disc Inc is a United States-based firm engaged in the manufacture and sale of marine and heavy-duty off-highway power transmission equipment. The company operates its business through two reportable segments: Manufacturing and Distribution. Its product portfolio includes marine transmissions, surface drives, propellers, and boat management systems as well as power-shift transmissions, hydraulic torque converters, power take-offs, industrial clutches, and control systems.
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.